Is Mitotane now covered by medical insurance?

Mitotane (Mitotane) is a drug specifically targeted at adrenocortical cancer (ACC; adrenal cancer ). Its mechanism of action mainly slows down tumor progression by selectively destroying adrenocortical cells and inhibiting hormone synthesis. SinceACC is a rare and highly malignant endocrine tumor with limited treatment options for patients, mitotane occupies a core position in postoperative adjuvant therapy and maintenance therapy for high-risk patients. The domestic mitotane specification is generally 500mg*100 tablets per box, and the price is about more than 9,000 yuan. The relative price is relatively high, which is mainly due to its research and development costs, import tariffs and clinical scarcity.

As of now, mitotane has not been included in the domestic medical insurance system, so patients need to bear all the drug costs themselves during use. Although it is not covered by medical insurance, its clinical value is still widely recognized, especially for patients with a high risk of recurrence or who cannot accept other treatments. Mitotane can provide an irreplaceable treatment option. When doctors prescribe mitotane, they usually make a comprehensive assessment based on the severity of the patient's condition, age, adrenal function, previous treatment history, and financial conditions to formulate a medication plan. For some patients with greater financial pressure, some hospitals or pharmaceutical companies may provide drug assistance programs or clinical trial channels to help patients ease their financial burden.

In addition to the medication itself, treatment management and monitoring are critical. Overseas guidelines recommend that blood concentration, liver function, kidney function, blood lipids and blood sugar and other indicators should be regularly monitored during mitotane treatment in order to adjust the dose in a timely manner to ensure efficacy while reducing toxic and side effects. In addition, patients should undergo regular imaging review to evaluate tumor changes and treatment response. Doctors may adjust treatment plans based on clinical indicators and imaging results.

Reference materials:https://go.drugbank.com/drugs/DB00648